Treatment adherence and quality of life in patients on antihypertensive medications in a Middle Eastern population: adherence

Alhaddad, Imad A.; Hamoui, Omar; Hammoudeh, Ayman; Mallat, Samir

doi:10.2147/vhrm.s105921

Cited by 47 publications

(55 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“… 3 In contrast, non-adherence to antihypertensive agents (AHA), mainly associated with uncontrolled blood pressure, can lead to long-term cardiovascular complications, 4 – 6 increased health system costs 7 – 11 and a poor quality of life. 12 Depending on the method used, adherence to AHA ranges between 16% and 77%. 13 …”

Section: Introductionmentioning

confidence: 99%

Out-of-pocket costs and adherence to antihypertensive agents among older adults covered by the public drug insurance plan in Quebec

Milan¹,

Vasiliadis²,

Guerra³

et al. 2017

PPA

View full text Add to dashboard Cite

ObjectiveTo evaluate the effect of patient out-of-pocket costs on adherence to antihypertensive agents (AHA) in community-dwelling older adults covered by the public drug insurance plan in Quebec.MethodsThis is a secondary analysis of data from the “Étude sur la santé des aînés” study (2005–2008) on community-dwelling older adults in Quebec aged 65 years and older (N=2,811). The final sample included 881 participants diagnosed with arterial hypertension and treated with AHA. Medication adherence was measured with the proportion of days covered over a 2-year follow-up period (<80% and ≥80%). Out-of-pocket costs for AHA, in Canadian dollars (CAD), at cohort entry were categorized as follows: $0, $0.01–$5.00, $5.01–$10.00, $10.01–$15.00 and $15.01–$36.00. Multivariable logistic regression models were constructed to study adherence to AHA as a function of out-of-pocket costs while controlling for several confounders. Models were also stratified by annual household income (<$15,000 CAD and ≥$15,000 CAD).ResultsIn this study, 80.8% of participants were adherent to their AHA. Among participants reporting an annual household income <$15,000 CAD, those with an out-of-pocket cost of $10.01–$15.00 CAD were significantly less adherent to their AHA than those with no contribution (OR =0.175, 95% CI: 0.042–0.740). Among participants reporting an income of ≥$15,000 CAD, those with out-of-pocket costs of $0.01–$5.00 CAD (OR =0.194; 95% CI: 0.048–0.787), $5.01–$10.00 CAD (OR =0.146; 95% CI: 0.036–0.589), $10.01–$15.00 CAD (OR =0.192; 95% CI: 0.047–0.777) and $15.01–$36.00 CAD (OR =0.160, 95% CI: 0.039–0.655) were significantly less adherent to their AHA than participants with no contribution.ConclusionIncreased out-of-pocket costs are associated with non-adherence to AHA in older adults covered by a public drug insurance plan, more importantly in those reporting an annual household income ≥$15,000 CAD. A reduction in the amount of out-of-pocket costs and yearly maximum contribution for drugs may improve adherence to treatment.

show abstract

Section: Introductionmentioning

confidence: 99%

Out-of-pocket costs and adherence to antihypertensive agents among older adults covered by the public drug insurance plan in Quebec

Milan¹,

Vasiliadis²,

Guerra³

et al. 2017

PPA

View full text Add to dashboard Cite

show abstract

“…Особую актуальность и значимость проблемы HRQoL и приверженности к терапии имеют при хро-нических заболеваниях, требующих длительного, не-редко пожизненного, лечения. В целом ряде иссле-дований была выявлена взаимосвязь между крите-риями КЖ и показателями приверженности к лечению [3][4][5]. Так, в публикации Allhadad I.A.…”

Section: Treatment Adherence and Quality Of Life Of Patients With Staunclassified

“…и соавт. по ре-зультатам международного наблюдательного иссле-дования была продемонстрирована ассоциация низкого КЖ пациентов с артериальной гипертонией и их плохой приверженностью к лечению [3]. В работе Perwitasari D.A.…”

Section: Treatment Adherence and Quality Of Life Of Patients With Staunclassified

Treatment Adherence and Quality of Life of Patients With Stable Ischemic Heart Disease in Treatment With Nicorandil: Interrelation and Interaction (According to the Results of the Observational Study Nikea)

Martsevich

Lukina

Кутишенко

et al. 2018

Racionalʹnaâ farmakoterapiâ v kardiologii

View full text Add to dashboard Cite

Aim. To assess quality of life (QoL) and its dynamics during nicorandil treatment in patients with stable ischemic heart disease, to study the relationship of treatment adherence and QoL indicators when treated with nicorandil.Material and methods. Observational program NIKEA included 590 patients with angina pectoris. Seattle Angina Questionnaire (SAQ) was used to assess QoL. Patients completed SAQ at the visit of inclusion (V0) and at the visit after 3 months of observation (V3). Potential and actual adherence to therapy was assessed by medical interviews at visits V0, V1 (1 month of observation) and V3. During the visit V0 417 people (from 590 ones enrolled into the study) completed SAQ (71% response); after 3 months (V3) SAQ was filled in by 454 of 552 people who came to this visit (82% response). According to the results of medical interviews, potential adherence (visit V0) was determined in all 590 patients, actual adherence to nicorandil (visits V1 and V3) was assessed in 552 patients who came to these visits. In accordance with the degree of adherence, all patients were divided into 3 groups: (1) adherent to treatment (taking nicorandil for the first three months), (2) non-adherent (who refused to take nicorandil), and (3) partially non-adherent (who started nicorandil, but for various reasons stopped taking the drug).Results. In all patients, regardless of their adherence to the recommended drug, there was an increase in QoL according to all five scales of the SAQ after 3 months of follow-up. Statistically significant positive dynamics of all SAQ indicators was found only in adherent patients (p<0.0001 for all aspects). Patients, who showed good adherence to nicorandil at V1, had more severe angina at the beginning of treatment (according to “Angina Stability” and “Angina Frequency” indicators). These patients also had lower QoL “Disease Perception” score and more confidence in the doctor (“Treatment Satisfaction” score) than non-adherent patients (p<0.05). In non-adherent patients a mild degree of angina was determined 2 times more often according to “Angina Frequency” indicator (p=0.03).Conclusion. The results of the study confirm the interrelation and mutual influence of the QoL indicators and treatment adherence to nicorandil. Effective treatment with nicorandil in patients with lower health-related QoL indicators could increase treatment adherence. On the other hand, the mild degree of angina, the low level of confidence in the treating doctor, the side effects of the new drug reduce medication adherence of patients, which, as a result, negatively affects the QoL of these patients

show abstract

“…Результаты продемонстрировали, что 55,9 % пациентов привержены к применению антигипертензивных препаратов. Фактор высокого комплаенса -это старший возраст, а факторы недо-статочного -развод / вдовство, низкие показатели качества жизни, АГ I или II стадии [11].…”

Section: материалы и методыunclassified

The Review of Modern Studys About the Importance of Compliance of Patients to Treatment of Сardiovascular Diseases

Соболева¹

2017

Klinicist

View full text Add to dashboard Cite

Treatment adherence and quality of life in patients on antihypertensive medications in a Middle Eastern population: adherence

Cited by 47 publications

References 25 publications

Out-of-pocket costs and adherence to antihypertensive agents among older adults covered by the public drug insurance plan in Quebec

Out-of-pocket costs and adherence to antihypertensive agents among older adults covered by the public drug insurance plan in Quebec

Treatment Adherence and Quality of Life of Patients With Stable Ischemic Heart Disease in Treatment With Nicorandil: Interrelation and Interaction (According to the Results of the Observational Study Nikea)

The Review of Modern Studys About the Importance of Compliance of Patients to Treatment of Сardiovascular Diseases

Contact Info

Product

Resources

About